Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
← catalyst calendarSponsored by aTyr Pharma, Inc. (industry) · ATYR — their whole pipeline →. With Kyorin Pharmaceutical Co.,Ltd.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
268actual
Sites
91
Countries
Brazil, France, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-15 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-14 | actual | The whole study's end, after follow-up |
| First posted | 2022-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Sarcoidosis
Interventions
- Drug: Efzofitimod 3 mg/kg — also filed as ATYR1923, KRP-R120
- Drug: Efzofitimod 5 mg/kg — also filed as ATYR1923, KRP-R120
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in mean daily oral corticosteroid (OCS) dose at Week 48
measured Baseline to Week 48
Publications
- PMID 37902990 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ATYR's whole pipeline · Catalyst calendar · Every registered study · What changed